Evidence map›Paper›PMID 23415223›Full record

ArticleCell2013

Xist RNA is a potent suppressor of hematologic cancer in mice.

Eda Yildirim, James E Kirby, Diane E Brown, Francois E Mercier, Ruslan I Sadreyev, David T Scadden, Jeannie T Lee

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04288739 (Relationship Between Immunophenotyping and X-inactive Specific Transcript), which is not on this map. Cited by 311 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
311citing papers in PubMed, 1 pooled it
41.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04288739 unknown statusnot on this mapstarted 2020, after this paper: background citation

Relationship Between Immunophenotyping and X-inactive Specific Transcript (Xist) Gene in Acute Myeloid Leukemia

TypeobservationalSponsorAssiut UniversityRan2020 to 2022Enrolled65ConditionsAcute Myeloid LeukemiaArmsflow cytometric immunophenotyping, Xist gene by fluorescence insitu hybridization
3 · Its place in the literature

Who cites it

311 citing papers in PubMed, 1 synthesis or guideline pooled it, 516 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. FASEB bioAdvances · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

251 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Eda YildirimHoward Hughes Medical Institute, Massachusetts General Hospital, Boston, MA 02114, USA.
James E Kirby
Diane E Brown
Francois E Mercier
Ruslan I Sadreyev
David T Scadden
Jeannie T Lee
Harvard University · USHoward Hughes Medical Institute · USBeth Israel Deaconess Medical Center · US

Funding

MECHANISMS OF HEMATOPOIESIS IN AIDSR01HL044851 · NHLBI · NEW ENGLAND DEACONESS HOSPITAL · PI SCADDEN, DAVID T · 1991 to 2015
$7.7M
CIHRHoward Hughes Medical InstituteNHLBI NIH HHS HL44851NHLBI NIH HHS R01 HL044851
6 · The paper itself

Abstract

X chromosome aneuploidies have long been associated with human cancers, but causality has not been established. In mammals, X chromosome inactivation (XCI) is triggered by Xist RNA to equalize gene expression between the sexes. Here we delete Xist in the blood compartment of mice and demonstrate that mutant females develop a highly aggressive myeloproliferative neoplasm and myelodysplastic syndrome (mixed MPN/MDS) with 100% penetrance. Significant disease components include primary myelofibrosis, leukemia, histiocytic sarcoma, and vasculitis. Xist-deficient hematopoietic stem cells (HSCs) show aberrant maturation and age-dependent loss. Reconstitution experiments indicate that MPN/MDS and myelofibrosis are of hematopoietic rather than stromal origin. We propose that Xist loss results in X reactivation and consequent genome-wide changes that lead to cancer, thereby causally linking the X chromosome to cancer in mice. Thus, Xist RNA not only is required to maintain XCI but also suppresses cancer in vivo.

Indexed as

Genes, Tumor SuppressorAnimalsBone MarrowFemaleGenes, LethalHematopoietic Stem CellsMaleMiceMyelodysplastic SyndromesMyeloproliferative DisordersPrimary MyelofibrosisRNA, Long NoncodingSplenomegalyX Chromosome InactivationRNA, Long NoncodingXIST non-coding RNA

Identifiers

PMID23415223
PMCPMC3875356
OpenAlexW2171577249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.